Literature DB >> 3927779

Treatment of oligozoospermia by tamoxifen: no evidence for direct testicular action.

W Krause, H M Hübner, U Wichmann.   

Abstract

The improvement of impaired spermatogenesis by tamoxifen is well documented. The antiestrogen seems to act via an enhancement of gonadotropin release from the hypophysis, but there is evidence for a direct testicular effect. Thus we studied the serum levels of gonadotropins and steroid hormones in 22 patients with idiopathic oligozoospermia. To study the direct testicular effect, we tested the response of 5 normal males to hCG prior to and after the application of tamoxifen. FSH levels showed a continuous increase in the patients during the three months of treatment, while the stimulation by LH-RH was not altered. In the case of LH the basal as well the stimulated levels increased. Mean levels of testosterone, 17-hydroxyprogesterone, androstenedione and estradiol increased significantly during treatment. Sperm counts of patients were found to be considerably higher after three months. In the normal males no differences in steroid levels as a response to hCG with and without tamoxifen treatment occurred. Our results give evidence, that the hormonal changes occurring under tamoxifen treatment are not due to a direct testicular effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927779     DOI: 10.1111/j.1439-0272.1985.tb01004.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  3 in total

Review 1.  Anti-estrogens and aromatase inhibitors: tamoxifen and testolactone.

Authors:  F Sciarra
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

Review 2.  [Drug therapy options for oligoasthenoteratozoospermia syndrome].

Authors:  M Trottmann; F M Köhn; M Dickmann; C G Stief; A J Becker
Journal:  Urologe A       Date:  2011-01       Impact factor: 0.639

3.  Tamoxifen treatment of oligozoospermia: a re-evaluation of its effects including additional sperm function tests.

Authors:  K Sterzik; B Rosenbusch; J Mogck; M Heyden; K Lichtenberger
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.